Twenty one patients with hormone resistant prostate cancer were entered in a phase II study of pirarubicin 70 mg/m2, as a single intravenous injection given at 21 day intervals. All patients had leukopenia (9 severe or life threatening) and 2 died of septicemia. Thrombocytopenia occurred in 5 patients (one life threatening) and anemia in 12 patients. One partial response of 3 months duration was documented. Pirarubicin 70 mg/m2 given intravenously at 21 day intervals causes severe hematological toxicity and has minimal therapeutic activity in patients with hormone resistant prostate cancer.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Umezawa H, Takahashi Y, Kinoshita M, Naganawa H, Masuda T, Ishizuka M, Tatsuta K, Takeuchi T: Tetrahydropyranyl derivatives of daunomycin and Adriamycin. J Antibiot 32:1082–1084, 1979
Dantchev D, Paintrand M, Hayat M, Borut C, Mathe G: Low heart and skin toxicity of a tetrahydropyranyl derivative of Adriamycin (THP-ADM) as observed by electron and light microscopy. J Antibiot 32:1085–1086, 1979
Miller AA, Schuelen ME, Kleeberg UR, Seeber S, Schmidt CG: Phase I study of Pirarubicin. Jnl of Cancer Res & Clin Oncol 114:91–94, 1988
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655, 1982
Murphy CP, Slack NH: Response criteria for the prostate of the USA National Prostate Cancer Project. The Prostate 1:375–382, 1980
Sridhar KS, Samy TSA, Agarwal RP, Duncan RC, Benedetto P, Krishan AG, Vogel CL, Feun LG, Savaraj NM, Richman SP, Zubrod CG: A Phase I–II study of 4′-0-tetrahydropyranyladriamycin. Clinical Pharmacology and Pharmacokinetics. Cancer 66:2082–2091, 1990
Pirarubicin was supplied by: Behringwerke AG, Marberg, Germany.
Supported in part by a grant from the National Cancer Association of South Africa.
About this article
Cite this article
Rapoport, B.L., Falkson, G. Phase II clinical study of pirarubicin in hormone resistant prostate cancer. Invest New Drugs 10, 119–121 (1992). https://doi.org/10.1007/BF00873129
- hormone resistant prostate cancer